Allogene Therapeutics, Inc.

Contributing Author

Recent Articles by Allogene Therapeutics, Inc.

Aug-13	Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update ALLO GlobeNewswire
Aug-06	Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update ALLO GlobeNewswire
Aug-01	Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma ALLO GlobeNewswire
Jun-01	Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO ALLO GlobeNewswire
May-23	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences ALLO GlobeNewswire
May-22	Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel ALLO GlobeNewswire
May-13	Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update ALLO GlobeNewswire
May-06	Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update ALLO GlobeNewswire